REG - Diaceutics PLC - Exercise of Warrant & Total Voting Rights

DiaceuticsAnnouncement

25/01/2024 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240125:nRSY9506Aa&default-theme=true

RNS Number : 9506A  Diaceutics PLC  25 January 2024

Diaceutics PLC - Exercise of Warrant & Total Voting Rights

 

Belfast and London, 25 January 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to pharma and biotech companies, announces
that it has received notification for the exercise of warrants over 177,915
ordinary shares of £0.002 each in the Company ("Ordinary Shares") at an
exercise price of £0.76 per share, providing the Company with proceeds
of £135,215 ("Warrant Exercise").

 

Application has been made to the London Stock Exchange to admit the 177,915
new ordinary shares resulting from the Warrant Exercise to trading on AIM
("Admission"), which is expected to occur on at 8:00 am tomorrow 26 January
2024.  The new Ordinary Shares will rank pari passu with the existing
Ordinary Shares. The Warrant Exercise completes all outstanding warrants.

 

Following Admission, the total issued share capital of the Company will
consist of 84,679,305 Ordinary Shares. This number may be used by shareholders
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500
 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network®

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRXELFLZFLFBBZ